LEO Pharma Finalizes Acquisition of Spevigo® for Rare Dermatologic Diseases
KEY TAKEAWAYS
LEO Pharma announced that it has officially acquired Spevigo®, the only approved IL-36R antagonist for generalized pustular psoriasis (GPP) flares.
The company plans to expand access and development for additional IL-36-mediated skin conditions.
LEO Pharma has officially completed its acquisition of Spevigo® (spesolimab) from Boehringer Ingelheim, according to a press release from the manufacturer.
The purchase represents the culmination of LEO Pharma's efforts to commercialze spevigo (reported in July by Practical Dermatology) which has been approved globally for the treatment of generalized pustular psoriasis (GPP) flares. It is currently the only IL-36 receptor antagonist on the market approved to treat GPP. It has been approved in more than 40 countries, including the U.S., Japan, China, and across Europe.
“LEO Pharma is uniquely positioned to take over Spevigo® and expand access to care,” said Christophe Bourdon, CEO of LEO Pharma. “We are committed to ensuring this innovative treatment reaches its full potential by building on Boehringer Ingelheim’s pioneering efforts.”
Beyond GPP, spesolimab is in clinical development for additional IL-36-mediated conditions such as pyoderma gangrenosum. LEO Pharma will take over full commercialization and further development responsibilities.
The press release noted that while the drug is expected to contribute less than one percent to LEO Pharma’s 2025 revenue growth, its addition reflects the company’s longer-term commitment to underserved patient populations in medical dermatology. Financial forecasts suggest a modest short-term EBITDA margin impact due to ongoing development costs, while full-year revenue and margin outlooks remain otherwise unchanged.
“Bringing Spevigo® to more patients is an important step in helping those living with GPP, a community with limited treatment options,” said Christophe Bourdon, CEO of LEO Pharma, in the press release. “We are committed to ensuring this innovative treatment reaches its full potential by building on Boehringer Ingelheim’s pioneering efforts.”
Source: LEO Pharma press release. October 2, 2025.